CMS proposes payment models for accelerated approval, gene & cell therapies

CMS has announced three new payment models that are intended to improve access to generic drugs, facilitate outcomes-based agreements for cell and gene therapies, and incentivize manufacturers to complete confirmatory trials of drugs that receive accelerated approval.

The proposed payment models are described in a report HHS Secretary Xavier Becerra submitted to President Joe Biden in response to an executive order that requested recommendations on actions the administration could take to lower drug prices. ...